Surely you are joking, Mr Docking!
Chem Soc Rev
; 52(3): 872-878, 2023 Feb 06.
Article
in English
| MEDLINE | ID: covidwho-2230297
ABSTRACT
In the wake of recent COVID-19 pandemics scientists around the world rushed to deliver numerous CADD (Computer-Aided Drug Discovery) methods and tools that could be reliably used to discover novel drug candidates against the SARS-CoV-2 virus. With that, there emerged a trend of a significant democratization of CADD that contributed to the rapid development of various COVID-19 drug candidates currently undergoing different stages of validation. On the other hand, this democratization also inadvertently led to the surge rapidly performed molecular docking studies to nominate multiple scores of novel drug candidates supported by computational arguments only. Albeit driven by best intentions, most of such studies also did not follow best practices in the field that require experience and expertise learned through multiple rigorously designed benchmarking studies and rigorous experimental validation. In this Viewpoint we reflect on recent disbalance between small number of rigorous and comprehensive studies and the proliferation of purely computational studies enabled by the ease of docking software availability. We further elaborate on the hyped oversale of CADD methods' ability to rapidly yield viable drug candidates and reiterate the critical importance of rigor and adherence to the best practices of CADD in view of recent emergence of AI and Big Data in the field.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Drug Design
/
COVID-19
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Chem Soc Rev
Year:
2023
Document Type:
Article
Affiliation country:
D2cs00948j
Similar
MEDLINE
...
LILACS
LIS